Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 1, 2011, Pages 153-162

  Okanoue, Takeshi ^a,b   Umemura, Atsushi ^a   Yasui, Kohichiroh ^b   Itoh, Yoshito ^b  

^a Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Diabetes mellitus; Metabolic syndrome; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; COLESTILAN; EZETIMIBE; FENOFIBRATE; GLUCOSE; NATEGLINIDE; PANTETHINE; PIOGLITAZONE; PROBUCOL; ROSIGLITAZONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHILDHOOD DISEASE; DIABETES MELLITUS; DIET THERAPY; DIETARY INTAKE; DYSLIPIDEMIA; GENETIC ANALYSIS; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; JAPAN; KINESIOTHERAPY; LIFESTYLE; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER INJURY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHLEBOTOMY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78650775102     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06547.x     Document Type: Review

References (73)

1. Hotta N, Nakamura J, Iwamoto Y et al. Causes of death in Japanese diabetics based on the results of a survey of 18 385 diabetics during 1991-2000. Report of Committee on Cause of Death in Diabetes Mellitus.J. Jpn. Diabetes Soc. 2007; 50: 47-61.
2. Dock JSoN. The report of 2008 National Summary of Ningen Dock, The 50th Scientific Meetings of Japan Society of Ningen Dock (in Japanese). Official J. Jpn. Soc. Ningen Dock. 2009; 24: 322.
3. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003; 38: 954-61.
4. Tanaka H, Saibara T. Genetic background of NASH and environmental factor. KAN.TAN.SUI ( in Japanese ). 2006; 53: 301-8.
5. Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143: 722-8.
6. Syndrome TECoCfM. The definition and criteria of metabolic syndrome. (in Japanese). J. Jpn. Soc. Intern. Med. 2005; 94: 794-809.
7. Welfare MoHLa. National Health and Nutrition Examination Survey in Japan (in Japanese). 2008.
8. Ishibashi E, Eguchi Y, Eguchi T et al. Waist circumference correlates with hepatic fat accumulation in male Japanese patients with non-alcoholic fatty liver disease, but not in females. J. Gastroenterol. Hepatol. 2008; 23: 908-13.
9. Sakurai M, Takamura T, Miura K, Kaneko S, Nakagawa H. Middle-aged Japanese women are resistant to obesity-related metabolic abnormalities. Metabolism 2009; 58: 456-9.
10. Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J. Gastroenterol. 2007; 13: 1579-84.
11. Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M. Etiology of liver cirrhosis in Japan: a nationwide survey. J. Gastroenterol. 2010; 45: 86-94.
12. Hepatology TJSo. The Medical Guide of NASH.NAFLD (in Japanese). 2010.
13. Welfare MoHLa. National Health and Nutrition Examination Survey in Japan (in Japanese). 2007.
14. Jimba S, Nakagami T, Takahashi M et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 2005; 22: 1141-5.
15. Miyaaki H, Ichikawa T, Nakao K et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int. 2008; 28: 519-24.
16. Shiga T, Moriyoshi Y, Nagahara H, Shiratori K. Nonalcoholic fatty liver is a risk factor for postprandial hyperglycemia, but not for impaired fasting glucose. J. Gastroenterol. 2009; 44: 757-64.
17. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
18. Fallo F, Dalla Pozza A, Sonino N et al. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. J. Hypertens. 2008; 26: 2191-7.
19. Donati G, Stagni B, Piscaglia F et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004; 53: 1020-3.
20. Yasui K, Sumida Y, Mori Y et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 2010; DOI: 10.1016/j.metabol.2010.07.022.
21. Tominaga K, Fujimoto E, Suzuki K, Hayashi M, Ichikawa M, Inaba Y. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environ. Health Prev. Med. 2009; 14: 142-9.
22. Tsuruta G, Tanaka N, Hongo M et al. Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits. J. Gastroenterol. 2010; 45: 666-72.
23. Weston SR, Leyden W, Murphy R et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41: 372-9.
24. Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J. Hepatol. 2009; 50: 797-804.
25. Jarrar MH, Baranova A, Collantes R et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008; 27: 412-21.
26. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J. Hepatol. 2007; 46: 1104-10.
27. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54.
28. Takahashi M, Arita Y, Yamagata K et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int. J. Obes. Relat. Metab. Disord. 2000; 24: 861-8.
29. Stumvoll M, Tschritter O, Fritsche A et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 2002; 51: 37-41.
30. Tokushige K, Hashimoto E, Noto H et al. Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease. J. Gastroenterol. 2009; 44: 976-82.
31. Yoneda M, Hotta K, Nozaki Y et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int. 2009; 29: 1078-85.
32. Nozaki Y, Saibara T, Nemoto Y et al. Polymorphisms of interleukin-1 beta and beta 3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis. Alcohol. Clin. Exp. Res. 2004; 28: S106-10.
33. Namikawa C, Shu-Ping Z, Vyselaar JR et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J. Hepatol. 2004; 40: 781-6.
34. Dong H, Wang J, Li C et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J. Hepatol. 2007; 46: 915-20.
35. Suzuki A, Abdelmalek MF. Nonalcoholic fatty liver disease in women. Womens Health (Lond Engl) 2009; 5: 191-203.
36. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-5.
37. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
38. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
39. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-74.
40. Okanoue T, Ohta M, Ou O et al. Relationship of Mallory bodies to intermediate filaments in hepatocytes. A scanning electron microscopy study. Lab. Invest. 1985; 53: 534-40.
41. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol. 2007; 102: 399-408.
42. Campos GM, Bambha K, Vittinghoff E et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008; 47: 1916-23.
43. Yilmaz Y, Dolar E, Ulukaya E et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J. Gastroenterol. 2007; 13: 837-44.
44. Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K. Correlation of hepatic steatosis with body mass index, serum ferritin level and hepatic fibrosis in Japanese patients with chronic hepatitis C. Hepatol. Res. 2007; 37: 263-9.
45. Sumida Y, Nakashima T, Yoh T et al. Serum thioredoxin elucidates the significance of serum ferritin as a marker of oxidative stress in chronic liver diseases. Liver 2001; 21: 295-9.
46. Sumida Y, Kanemasa K, Itoh Y, Yoshikawa T. A proposal of simple scoring system to differentiate nonalcoholic steatohepatitis from nonalcoholic fatty liver disease: we originally named NAFIC score composed of serum ferritin, fasting insulin, type? collagen 7S. Kanzo 2008; 49: 279-81.
47. Fujii H, Enomoto M, Fukushima W et al. Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J. Gastroenterol. 2009; 44: 608-14.
48. de Andrade AR, Cotrim HP, Alves E et al. Nonalcoholic fatty liver disease in severely obese individuals: the influence of bariatric surgery. Ann. Hepatol. 2008; 7: 364-8.
49. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol. Clin. Biol. 2008; 32: 22-39.
50. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
51. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7.
52. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut 2009; 58: 1566-7. author reply 7.
53. Park H, Ishigami A, Shima T et al. Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. J. Gastroenterol. 2010; 45: 426-34.
54. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
55. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch. Intern. Med. 2006; 166: 1871-7.
56. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J. Gastroenterol. Hepatol. 2009; 24: 248-54.
57. Hashimoto E, Yatsuji S, Tobari M et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol. 2009; 44 (Suppl. 19): 89-95.
58. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
59. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 1997; 27: 103-7.
60. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 1999; 353: 1802.
61. Dohmen K, Wen CY, Nagaoka S et al. Fenofibrate-induced liver injury. World J. Gastroenterol. 2005; 11: 7702-3.
62. Hyogo H, Tazuma S, Arihiro K et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57: 1711-8.
63. Nozaki Y, Fujita K, Yoneda M et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J. Hepatol. 2009; 51: 548-56.
64. Park H, Shima T, Okanoue T. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J. Gastroenterol. 2010; DOI: 10.1007/s00535-010-0291-8.
65. Yoshiji H, Noguchi R, Ikenaka Y et al. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res. Notes 2009; 2: 70.
66. Fujita K, Yoneda M, Wada K et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig. Dis. Sci. 2007; 52: 3455-64.
67. Yokohama S, Tokusashi Y, Nakamura K et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J. Gastroenterol. 2006; 12: 322-6.
68. Morita Y, Ueno T, Sasaki N et al. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology 2005; 52: 1338-43.
69. Tokushige K, Hashimoto E, Yatsuji S, Taniai M, Shiratori K. Combined pantethine and probucol therapy for Japanese patients with non-alcoholic steatohepatitis. Hepatol. Res. 2007; 37: 872-7.
70. Taniai M, Hashimoto E, Tobari M et al. Treatment of nonalcoholic steatohepatitis with colestimide. Hepatol. Res. 2009; 39: 685-93.
71. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment. Pharmacol. Ther. 2001; 15: 1667-72.
72. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010; 362: 1675-85.
73. Sumida Y, Kanemasa K, Fukumoto K et al. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: a pilot study. Hepatol. Res. 2006; 36: 315-21.